Treatment of Ureaplasma Infection
For confirmed Ureaplasma infection in adults, doxycycline 100 mg orally twice daily for 7 days is the first-line treatment; pregnant patients should receive azithromycin 1 g orally as a single dose; and neonates should be treated with erythromycin base or ethylsuccinate 50 mg/kg/day divided into four doses for 14 days.
Adults (Non-Pregnant)
The standard approach for adult Ureaplasma infection follows treatment protocols established for non-gonococcal urethritis, as Ureaplasma urealyticum causes 20-40% of these cases 1.
First-line therapy:
- Doxycycline 100 mg orally twice daily for 7 days 1
Alternative regimens (for tetracycline intolerance):
- Erythromycin base 500 mg orally 4 times daily for 7 days
- Erythromycin ethylsuccinate 800 mg orally 4 times daily for 7 days 1
Resistant or Persistent Infections
For patients with persistent symptoms after initial doxycycline treatment, the alternative regimen should be extended to 14 days (e.g., erythromycin base 500 mg orally 4 times daily for 14 days). This extended macrolide therapy addresses possible tetracycline-resistant U. urealyticum 1.
Recent susceptibility data shows:
- Doxycycline: 100% susceptibility 2
- Josamycin: 93.33% susceptibility 2
- Clarithromycin and azithromycin: variable resistance (40-80% cross-resistance with erythromycin) 3
- Fluoroquinolones (ofloxacin, ciprofloxacin): >80% resistance rates 2
Critical caveat: Fluoroquinolones should be avoided as empiric therapy due to high resistance rates and poor efficacy against urogenital mycoplasmas 3, 2.
Pregnant Patients
Pregnant women must not receive doxycycline, tetracyclines, or fluoroquinolones 4, 5.
Recommended treatment:
- Azithromycin 1 g orally as a single dose 4
Alternative for extended therapy:
- Erythromycin base or amoxicillin (for chlamydial co-infection considerations) 5
The macrolide class is preferred during pregnancy due to established safety profiles. Azithromycin has been successfully used to treat pregnant women with related infections without complications to mothers or infants 6.
Neonates
Neonatal Ureaplasma infection can result from vertical transmission and may cause respiratory complications, bronchopulmonary dysplasia, and neurodevelopmental impairment 7, 8.
Recommended treatment:
- Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses for 14 days 4
Important considerations for neonates:
- Treatment duration of 3-10 weeks has been reported in severe cases (e.g., meningitis) 8
- Macrolides (particularly azithromycin) are commonly used for 3 weeks in respiratory infections 8
- Monitor for potential adverse effects including hepatotoxicity and the association between oral erythromycin and infantile hypertrophic pyloric stenosis 4
- Tetracyclines are contraindicated in neonates and children <8 years due to dental staining and bone growth effects 9
Neonatal Meningitis
For U. parvum meningitis specifically, azithromycin for 3 weeks has shown favorable outcomes, though some cases required 3-10 weeks of treatment. Macrolides combined with quinolones have been used in severe cases, but optimal regimen and duration remain unclear 8.
Macrolide- or Tetracycline-Resistant Strains
When resistance is documented or suspected:
For macrolide-resistant strains:
- Switch to doxycycline 100 mg orally twice daily for 7-14 days (if not already used)
- Josamycin shows better activity than other macrolides and may overcome some erythromycin resistance 3
For tetracycline-resistant strains:
- Extended macrolide therapy: erythromycin base 500 mg orally 4 times daily for 14 days 1
- Josamycin (where available) demonstrates superior activity 3
For dual-class resistance:
- Lefamulin (pleuromutilin class) shows potent in vitro activity with MIC50/90 of 0.25/1 mg/L for Ureaplasma species, even against macrolide- and clindamycin-resistant strains 10
- This represents a promising alternative when standard therapies fail, though clinical efficacy data for urogenital infections are still emerging
Avoid fluoroquinolones as resistance rates exceed 80% for both ofloxacin and ciprofloxacin 2.
Common Pitfalls
- Do not use fluoroquinolones empirically - resistance is widespread and efficacy is poor 3, 2
- Do not use β-lactam antibiotics - Ureaplasma lacks a cell wall and is naturally resistant 11
- Do not undertreated persistent infections - extend therapy to 14 days with alternative agents rather than repeating the same regimen 1
- Do not forget partner treatment - sex partners should be evaluated and treated to prevent reinfection 1
- Monitor neonates for treatment failure - some cases require extended therapy beyond standard 14-day courses 8